Twenty-Three Years from Error to Correction: The Hormone Therapy Catastrophe and the Urgent Case for Regulatory Reform

Background On November 10, 2025, the U.S. Food and Drug Administration rescinded 23-year-old black-box warnings on hormone therapy, acknowledging what FDA Commissioner Marty Makary termed possibly one of the greatest medical errors of modern times. The regulatory failure caused an estimated 91,000 premature deaths among women aged 50-59 between 2002 and 2012 alone, with approximately 50 million women denied potentially life-saving treatment. Objective To examine why correction of hormone therapy policy required 23 years despite early scientific critique and accumulating contrary evidence, and to propose mandatory structural reforms to prevent similar regulatory catastrophes. Evidence Review This analysis draws on published peer-reviewed studies, FDA regulatory documents and announcements, mortality data analyses, the 2025 FDA Expert Panel proceedings, and Federal Register public comments. The 2002 Women’s Health Initiative study tested one formulation in women averaging 63 years old yet generated class-wide warnings for all hormone preparations and patient populations. Current evidence demonstrates that hormone therapy initiated within 10 years of menopause reduces fatal cardiovascular events by 25-50%, cognitive decline by 64%, Alzheimer’s disease by 35%, and fractures by 50-60%. Findings Three systemic barriers prevented timely correction: (1) statistical presentation that amplified relative risk whilst obscuring absolute risk, transforming a modest finding into categorical contraindication; (2) institutional structures rewarding restriction over reassessment, with no mechanisms for mandatory re-evaluation; and (3) cognitive biases that privileged fear over evidence, requiring disproportionate proof to overcome initial warnings despite accumulating contradictory data from randomised trials and observational studies. Conclusion and Relevance Five mandatory reforms are required: proportional regulatory response matching evidence specificity, five-year sunset clauses for all black-box warnings requiring formal reassessment, formal mechanisms for external methodological critique to trigger regulatory review, transparent absolute risk communication as a regulatory requirement, and urgent reinvestment in menopausal medicine subspecialty training. These structural reforms represent the minimum requirements to prevent recurrence. The hormone therapy catastrophe demonstrates that in medicine, where time directly translates to outcomes, changing course when evidence indicates current policy harms more than helps constitutes an ethical imperative, not merely a scientific correction.